更新于：2024-11-01

Rajavithi Hospital

Thailand

更新于：2024-11-01

概览

概览

关联

135

项与 Rajavithi Hospital 相关的临床试验

NCT06665737 / Not yet recruiting临床4期IIT

A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study

The goal of this clinical trial is to
Primary Objectives:
1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study
2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study
Secondary Objectives:
1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.
2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).
All patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.

开始日期2024-12-01

申办/合作机构

Rajavithi Hospital

[+1]

TCTR20241011001 / Not yet recruiting早期临床1期IIT

Impact of using elastic abdominal binder on postoperative pain in woman after repeated cesarean section; An open-label randomized control trial

开始日期2024-10-15

申办/合作机构

Rajavithi Hospital

TCTR20240923004 / Not yet recruiting临床4期IIT

Comparison of the Radiologic and Clinical Outcomes of Patellar in Restricted Kinematic Alignment and Mechanical Alignment in Bilateral Total Knee Arthroplasty Patients, A Randomized Controlled Trial

开始日期2024-10-01

申办/合作机构

Rajavithi Hospital

100 项与 Rajavithi Hospital 相关的临床结果

登录后查看更多信息

0 项与 Rajavithi Hospital 相关的专利（医药）

登录后查看更多信息

601

项与 Rajavithi Hospital 相关的文献（医药）

2024-12-01·Exploratory Research in Clinical and Social Pharmacy

Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation at a tertiary care hospital in Thailand

Article

作者: Rungruang, Ratiya ; Pongsathabordee, Chayanat ; Saringkarn, Piyachat ; Tangkaotong, Pimlada ; Ratanapornsompong, Kanjana ; Sena, Salintip ; Paiboonvong, Taniya ; Srithonrat, Saranporn

BackgroundAppropriate dosing of direct oral anticoagulants (DOACs) has been associated with clinical efficacy and safety. Several studies have shown that DOAC dosing are often inconsistent with guideline recommendations. Little is known about this issue in Thailand. This study aimed to evaluate the appropriateness of DOAC dosing in Thai hospitalized patients with atrial fibrillation (AF).MethodThis was a retrospective descriptive study conducted on hospitalized patients at Rajavithi Hospital, a tertiary care hospital in Thailand. Inpatients diagnosed with AF and treated with DOACs between February 2021 and February 2023 were enrolled in the study. The appropriate dosing of DOACs was assessed according to the recommendation of the 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (EHRA). Descriptive statistics were used to analyze the data; median (interquartile range) for continuous variables, and numbers and percentages for categorical variables.ResultsA total of 120 patients with AF were evaluated for dosing. The patients received rivaroxaban in 47 cases (39.2 %), apixaban in 32 cases (26.7 %), edoxaban in 31 cases (25.8 %), and dabigatran in 10 cases (8.3 %). Most of the patients were elderly, with a median age of 77.5 (68-84) years. Females were predominant (57.5 %). Our findings indicate that the prevalence of appropriate dosing of DOACs was 63.3 %. However, approximately one-third of patients received inappropriate dosing, with 24 (20.0 %) being overdosed, and 20 (16.7 %) being underdosed. The highest overdosing and underdosing rates were seen in dabigatran (90.0 %) and apixaban (21.9 %), respectively.ConclusionInappropriate dosing of DOACs according to the 2021 EHRA recommendations was high in 36.7 %, with overdosing mostly occurring in 20.0 %. The high number of inappropriate dosing highlights the need for implementation of optimal strategies to select the appropriate dose of DOACs in Thai hospitalized patients with AF.

2024-10-01·Ophthalmology and Therapy

Utilizing Large Language Models in Ophthalmology: The Current Landscape and Challenges

Review

作者: Chotcomwongse, Peranut ; Ruamviboonsuk, Paisan ; Grzybowski, Andrzej

2024-09-01·Transplantation

241.11: The temporal and long-term impact of combined donor-recipient height and gender mismatch on allograft outcome after kidney transplantation in Thailand: an analysis of the national transplant registry.

作者: Santisiripat, Chumpol ; Phonphok, Korntip

项与 Rajavithi Hospital 相关的新闻（医药）

2024-10-17

·mobihealthnews

Google licenses AI diabetic retinopathy model to partners in India, Thailand

Google announced it is licensing its AI model focused on detecting diabetic retinopathy to partners in Thailand and India, two countries the tech giant says have a shortage of eye specialists. Google Research teams partnered with foundational research partners Aravind Eye Hospital in India and Rajavithi Hospital in Thailand nearly a decade ago to research whether AI could be used to help reduce preventable blindness caused by diabetic retinopathy. Today, the company announced it is partnering with healthcare providers and health-tech partners across the countries to distribute the developed AI-enabled diabetic retinopathy model to improve access to eyesight-saving care. Google's newly announced partners include India-based medical equipment manufacturer Forus Health, nonprofit ophthalmic manufacturing company AuroLab and Thailand-based AI-enabled medical imaging technology company Perceptra. "We’ve also been working with the Thai Ministry of Public Health’s Department of Medical Services (DMS), which is responsible for the country’s diabetic retinopathy screening program, on implementation research and cost-effectiveness analysis. This collaboration is bringing our AI into Thailand’s National Innovation program and will pave the way for a partnership between Perceptra and DMS to apply the diabetic retinopathy AI model in public sector hospitals and help deliver impact at population scale," Google wrote in a blog post. The partners will work toward receiving local regulatory approvals to ensure clinical systems in both countries have access to the AI model, The organizations have also set a goal to deliver six million AI-enabled screenings to communities in need at no cost to patients over the next decade. THE LARGER TREND In a study published in the Indian Journal of Ophthalmology, researchers stated that the number of people with diabetic retinopathy globally will increase from 126.6 million in 2010 to 191 million by 2030, with vision-threatening diabetic retinopathy rising from 37.3 million to 56.3 million. In 2022, a study published out of Thailand in The Lancet revealed that deep learning algorithms could diabetic retinopathy in patients with diabetes on par with community specialists. Researchers discovered that the deep-learning system could detect vision-threatening diabetic retinopathy with 94.7% accuracy, 91.4% sensitivity and 95.4% specificity. This was compared to the retina specialist over-readers, who performed with an accuracy of 93.5%, a sensitivity of 84.8% and a specificity of 95.5%. In 2019, Alphabet's life science subsidiary Verily unveiled real-world clinical use for its machine learning algorithm to screen for diabetes-related conditions, including diabetic retinopathy and diabetic macular edema. The tool was first rolled out in India and aimed at helping with the shortage of doctors worldwide.